White House Launches Additional Test-to-Treat Sites

 Leverages Paxlovid to reduce hospitalization by 90%.

Last week, the White House announced the expansion of oral antiviral locations for COVID-19. The FDA authorized the oral antiviral pill Paxlovid for emergency use during the pandemic, and over the past 6 months, the use of these pills has reduced COVID-19 related hospitalization and death by around 90 percent.

The pills were distributed through “Test-to-Treat” sites throughout the United States. To continue addressing COVID-19, President Biden’s administration intends to double the places where Paxlovid is available.

“The tools we have now mean that we can prevent most COVID deaths,” said the White House. “The Administration remains laser-focused on making sure that these lifesaving tools are widely available to every American who needs them.”

As the Lord Leads, Pray with Us…

  • For officials in the FDA as they evaluate and approve therapies and interventions.
  • For protection and healing for the vulnerable who are exposed to COVID-19.
  • For the president and executive branch as they continue to address the coronavirus and its various strains.

Sources: The White House


Back to top